Valera Pharmaceuticals, a specialty biopharmaceutical company developing treatments for urological and endocrine disorders, announced the terms for its upcoming IPO on Tuesday. According to an amended SEC filing, the Cranbury, NJ based company plans to offer 3.75 million shares at a range of $10-$12 and has a proposed market cap of $162 million. Lead underwriter UBS Investment Bank has yet to determine a specific pricing date for the IPO.
